Nomura Holdings
TVTX icon

Nomura Holdings’s Travere Therapeutics TVTX Stock Holding History

Nomura Holdings’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-56,000
Closed -$1M – 1951
2025
Q1 		$1M Sell
56,000
-50,000
-47% -$1.01M ﹤0.01% 1277
2024
Q4 		$1.85M Buy
+106,000
New +$1.87M ﹤0.01% 1169

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nomura Holdings's TVTX Position: Q1 2026 in Review

Nomura Holdings sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 27,241 shares — an estimated $814K sold.

Nomura Holdings first reported a position in TVTX in Q2 2019 and held it in 6 quarters. The position peaked at $2.38M in Q2 2020. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Nomura Holdings reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Nomura Holdings sold 27,241 Travere Therapeutics shares in Q1 2026, an estimated $814K.
  • Nomura Holdings first reported a position in Travere Therapeutics in Q2 2019 and held it in 6 quarters.
  • Nomura Holdings's Travere Therapeutics position peaked at $2.38M in Q2 2020.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.